Delaware is the US’s go-to venue for pharma patent litigation, but there could be trouble ahead

Delaware is the US’s go-to venue for pharma patent litigation, but there could be trouble ahead

A burgeoning caseload and the retirement of key specialist judges might adversely affect the performance of the US district court for the District of Delaware in pharma patent litigation, according to Owen Byrd, general counsel and chief evangelist…

Unlock unlimited access to all IAM content